Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes clinical trials
How each study uses Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Catherine Bollard (2) · Children's National Research Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes.
Studies
Open first, then newest update. How each study uses Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid TumorsRecruitingPhase 1Children's National Research InstituteNCT05238792Written as Tumor-associated antigen-specific T cell (TAA-T)How we know
- Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic MalignanciesRecruitingPhase 1Catherine BollardNCT02203903Written as Tumor associated antigen lymphocytes (TAA-T)How we know
- Multi-antigen T Cell Infusion Against Neuro-oncologic DiseaseActive, not recruitingPhase 1Catherine BollardNCT03652545Written as TAA-THow we know